Tivozanib vs sorafenib (targeted agent versus targeted agent)
Progression‐free survival · Treatment‐naïve metastatic renal cell carcinoma (clear cell type)
Tivozanib may leads to lower progression‐free survival (absolute effect size estimates based on… compared with sorafenib (targeted agent versus targeted agent) (low certainty).
1 finding from 1 review
- HR 0.79 [0.64, 0.99]1 study · 517 participantsLow